AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9346222 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/paclitaxel
Number of subjects: 518
Study 8251273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with clonidine 120 micrograms
Number of subjects: 42
Study 8251273 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 42
Study 3739819 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior monitoring treatment
Number of subjects: 173
Study 3739819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no behavior monitoring)
Number of subjects: 173
Study 30486717 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fantasy condition
Number of subjects: 113
Study 30486717 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 113
Study 31332099 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen (paclitaxel 90 mg/m2 on days 1, 8, and 15 with carboplatin AUC 6 on day 1 of every 4 weeks)
Number of subjects: 140
Study 31332099 — intervention group
Group type: COMPARATOR
Intervention: Biweekly regimen (paclitaxel 135 mg/m2 with carboplatin AUC 3 on days 1 and 15 of every 4 weeks)
Number of subjects: 140
Study 29634142 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with alpha-blockers
Number of subjects: 90
Study 29634142 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-alpha reductase inhibitors and alpha-blockers
Number of subjects: 90
Study 29634142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination drug Duodart
Number of subjects: 90
Study 29634142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 28797281 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the affected leg for 45 minutes daily, 5 days a week for 3 weeks at a frequency of 10 Hz and pulse width of 200 μs.
Number of subjects: 100
Study 28797281 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (SHAM) delivered with the same modalities as TENS but with voltage falling to zero after 10 seconds.
Number of subjects: 100
Study 28797281 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS intervention.
Number of subjects: 100
Study 26261157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior PPM
Number of subjects: 2531
Study 26261157 — intervention group
Group type: EXPERIMENTAL
Intervention: New PPM
Number of subjects: 2531
Study 26261157 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB/no PPM
Number of subjects: 2531
Study 26261157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior PPM, New PPM, LBBB/no PPM
Number of subjects: 2531
Study 23835365 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (PLZ) 150 mg/d (116 mg CAR and 34 mg zinc)
Number of subjects: 42
Study 23835365 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnosine (CAR) 116 mg/d
Number of subjects: 42
Study 23835365 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 42
Study 21502883 — intervention group
Group type: COMPARATOR
Intervention: CT (circuit training)
Number of subjects: 38
Study 21502883 — intervention group
Group type: COMPARATOR
Intervention: CT + MI (circuit training + motivational interviewing)
Number of subjects: 38
Study 18199798 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1435
Study 18199798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435
Study 17023720 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (250 mg vitamin C, 100 IU vitamin E, 37.5 mg selenium)
Number of subjects: 3411
Study 17023720 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplementation (200 mg aged garlic extract and 1 mg steam-distilled garlic oil, twice daily)
Number of subjects: 3411
Study 17023720 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term amoxicillin (1 g) and omeprazole (20 mg) treatment
Number of subjects: 3411
Study 12710322 — intervention group
Group type: EXPERIMENTAL
Intervention: DER + 5 J
Number of subjects: 96
Study 12710322 — intervention group
Group type: COMPARATOR
Intervention: DER + 10 J
Number of subjects: 96
Study 10745279 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt fermented with one strain of Enterococcus faecium and two strains of Streptococcus thermophilus (CAUSIDO(R) culture), GAIO(R) (G)
Number of subjects: 70
Study 10745279 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt fermented with two strains of Streptococcus thermophilus and two strains of Lactobacillus acidophilus (StLa)
Number of subjects: 70
Study 10745279 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills (PP)
Number of subjects: 70
Study 10745279 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt fermented with two strains of Streptococcus thermophilus and one strain of Lactobacillus rhamnosus (StLr)
Number of subjects: 70
Study 10745279 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo yoghurt fermented with delta‐acid‐lactone (PY)
Number of subjects: 70
Study 8734726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotz's plate
Number of subjects: 20
Study 8734726 — intervention group
Group type: COMPARATOR
Intervention: No Hotz's plate
Number of subjects: 20
Study 1531820 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 111
Study 1531820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 31711737 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation for prostate cancer radiotherapy
Number of subjects: 0
Study 31711737 — intervention group
Group type: COMPARATOR
Intervention: Seven or less fractions
Number of subjects: 0
Study 30854452 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage (univariate predictor)
Number of subjects: 291
Study 30854452 — intervention group
Group type: EXPERIMENTAL
Intervention: MTV plus penumbra texture feature (added to stage)
Number of subjects: 291
Study 30854452 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model (including stage and MTV plus penumbra texture feature)
Number of subjects: 291
Study 28353040 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% phenylbutyrate mouthwash
Number of subjects: 0
Study 28353040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26551263 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of velpatasvir once daily
Number of subjects: 0
Study 26551263 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of velpatasvir plus ribavirin
Number of subjects: 0
Study 26551263 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of velpatasvir once daily
Number of subjects: 0
Study 26551263 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of velpatasvir plus ribavirin
Number of subjects: 0
Study 23648576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-soaked cottonoid
Number of subjects: 43
Study 23648576 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked cottonoid
Number of subjects: 43
Study 21134456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine formulations (PRP-T, 12μg; PRP-OMPC, 3μg or 6μg)
Number of subjects: 756
Study 21134456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine formulations (PRP-OMPC, 3μg or 6μg)
Number of subjects: 756
Study 21134456 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.5mL intramuscular dose of diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b+hepatitis B vaccine)
Number of subjects: 756
Study 20407301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (10 Hz) stimulation
Number of subjects: 18
Study 20407301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) stimulation
Number of subjects: 18
Study 20407301 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 20407301 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including low-frequency and sham)
Number of subjects: 18
Study 17174559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion at a dose of 0.1mg/kg/h during rewarming period of CPB
Number of subjects: 240
Study 17174559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SNP infusion)
Number of subjects: 240
Study 16686066 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS Group (81 patients undergoing CEUS before RFA)
Number of subjects: 164
Study 16686066 — intervention group
Group type: COMPARATOR
Intervention: Control Group (83 patients not undergoing CEUS before RFA)
Number of subjects: 164
Study 12483170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5 microg/kg/min for 20 min after aortic crossclamp release)
Number of subjects: 20
Study 12483170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium nitroprusside)
Number of subjects: 20
Study 9665357 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 10
Study 7647542 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BYHWD)
Number of subjects: 102
Study 7647542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 2620311 — intervention group
Group type: EXPERIMENTAL
Intervention: Step exercise test in hypoxia
Number of subjects: 8
Study 2620311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp exercise test in hypoxia
Number of subjects: 8
Study 8413 — intervention group
Group type: EXPERIMENTAL
Intervention: Health assistant guided by the protocol and supported by an available physician
Number of subjects: 567
Study 8413 — intervention group
Group type: COMPARATOR
Intervention: Physician only
Number of subjects: 567
Study 30892797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush + 0.12% chlorhexidine (CHX) rinsing
Number of subjects: 30
Study 30892797 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine (CHX) rinsing + manual toothbrush on day 14
Number of subjects: 30
Study 27646937 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 μg/kg/min
Number of subjects: 90
Study 27646937 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 μg/kg/min
Number of subjects: 90
Study 27646937 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 μg/kg/min
Number of subjects: 90
Study 27646937 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including all doses of remifentanil)
Number of subjects: 90
Study 27941730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day) for 12 weeks
Number of subjects: 98
Study 27941730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 27941730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day) for 12 weeks in participants with higher baseline serum uric acid levels
Number of subjects: 98
Study 24721334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) intervention (n=24) consisting of 1 week of therapist-supervised practices of daily tasks using SR of one's own performance (five 1-h sessions)
Number of subjects: 44
Study 24721334 — intervention group
Group type: COMPARATOR
Intervention: Functional rehabilitation (control; n=20) intervention practicing the same daily tasks with a therapist's demonstration and guidance
Number of subjects: 44
Study 24721334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) intervention
Number of subjects: 44
Study 22050871 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body hypothermia
Number of subjects: 204
Study 22050871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypothermia)
Number of subjects: 204
Study 19173749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 108
Study 19173749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 17499360 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer chelation therapy
Number of subjects: 161
Study 17499360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 15479125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels in women with aCAD(+), median 442 units/l, p<0.001
Number of subjects: 530
Study 15479125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels in men with aCAD(+), median 274 units/l, p<0.001
Number of subjects: 530
Study 15479125 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol levels in women with aCAD(+), 1.09 mmol/l, p<0.05
Number of subjects: 530
Study 15479125 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides in women with aCAD(+), 1.82 mmol/l, p<0.05
Number of subjects: 530
Study 15479125 — intervention group
Group type: EXPERIMENTAL
Intervention: Log(TG/HDL-C) in women with aCAD(+), higher than in women with aCAD(-)
Number of subjects: 530
Study 15479125 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) levels in men with aCAD(-), median 138 units/l
Number of subjects: 530
Study 15479125 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) levels in women with aCAD(-), median 145 units/l
Number of subjects: 530
Study 11463010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued oral anticoagulant therapy for 9 additional months
Number of subjects: 267
Study 11463010 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of oral anticoagulant therapy after 3 months
Number of subjects: 267
Study 11463010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy during the initial 9 months after randomization
Number of subjects: 267
Study 11463010 — intervention group
Group type: COMPARATOR
Intervention: Incidence of recurrence after discontinuation of treatment
Number of subjects: 267
Study 11463010 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of recurrence after continued therapy
Number of subjects: 267
Study 11463010 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended period of anticoagulant therapy
Number of subjects: 267
Study 9750033 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (cisplatin + etoposide) plus radiotherapy followed by surgery
Number of subjects: 0
Study 9750033 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (cisplatin + etoposide) plus radiotherapy followed by additional radiotherapy and 2 additional cycles of chemotherapy
Number of subjects: 0
Study 8032575 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong (once-daily evening administration)
Number of subjects: 18
Study 8032575 — intervention group
Group type: COMPARATOR
Intervention: Euphylong (twice-daily administration)
Number of subjects: 18
Study 3288432 — intervention group
Group type: EXPERIMENTAL
Intervention: Picenadol 25 mg
Number of subjects: 178
Study 3288432 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 178
Study 3288432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 31101545 — intervention group
Group type: EXPERIMENTAL
Intervention: BES (biodegradable polymer biolimus-eluting stent)
Number of subjects: 588
Study 31101545 — intervention group
Group type: COMPARATOR
Intervention: EES (durable polymer everolimus-eluting stent)
Number of subjects: 588
Study 28300856 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate Lotion, 0.05% (HBP Lotion)
Number of subjects: 2
Study 28300856 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate Cream, 0.05% (HBP Cream)
Number of subjects: 2
Study 26429056 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LR)
Number of subjects: 131
Study 26429056 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection (OR)
Number of subjects: 131
Study 23624701 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 0
Study 23624701 — intervention group
Group type: COMPARATOR
Intervention: Non‐surgical management (NSM)
Number of subjects: 0
Study 23624701 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP) and Non‐surgical management (NSM)
Number of subjects: 0
Study 21722582 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded continuous glucose monitoring (CGM)
Number of subjects: 46
Study 21722582 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment periods of prandial insulins
Number of subjects: 46
Study 21722582 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-in period
Number of subjects: 46
Study 21722582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 46
Study 19703277 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with residents
Number of subjects: 18
Study 17295560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 355
Study 17295560 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy weight intervention
Number of subjects: 355
Study 17295560 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 355
Study 16225489 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 2766
Study 16225489 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 20 mg
Number of subjects: 2766
Study 11899817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peloidobalneotherapy (daily procedures with 4-5 hours interval)
Number of subjects: 124
Study 11899817 — intervention group
Group type: COMPARATOR
Intervention: Peloidobalneotherapy (every other day)
Number of subjects: 124
Study 10421182 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf-thigh sequential pneumatic compression
Number of subjects: 149
Study 10421182 — intervention group
Group type: COMPARATOR
Intervention: Plantar venous intermittent pneumatic compression
Number of subjects: 149
Study 7588920 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 36
Study 7588920 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36
Study 7588920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7588920 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE Inhibition (Captopril and Enalapril)
Number of subjects: 36
Study 7588920 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Natriuretic Peptide
Number of subjects: 36
Study 7588920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Natriuretic Peptide
Number of subjects: 36
Study 2285255 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus MLT (10 mg/day orally at 8.00 p.m.)
Number of subjects: 33
Study 2285255 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 33
Study 7013894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 0.5 mg and heparin 5000 units subcutaneously, given 8-hourly in separate injection sites
Number of subjects: 0
Study 7013894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine alone
Number of subjects: 0
Study 7013894 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 7013894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine/heparin-treated patients
Number of subjects: 0
Study 31122901 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy (carboplatin and nab-paclitaxel)
Number of subjects: 724
Study 31122901 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 724
Study 28538025 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand Up Victoria intervention (12-month multicomponent workplace intervention)
Number of subjects: 231
Study 28538025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 231
Study 25148955 — intervention group
Group type: EXPERIMENTAL
Intervention: FVOO (30 mL, OOPC=961 mg/kg)
Number of subjects: 13
Study 25148955 — intervention group
Group type: COMPARATOR
Intervention: VOO (30 mL, OOPC=289 mg/kg)
Number of subjects: 13
Study 25148955 — intervention group
Group type: EXPERIMENTAL
Intervention: FVOO (30 mL)
Number of subjects: 13
Study 23511366 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position with 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 75
Study 23511366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lateral position with 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 75
Study 23511366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position with 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 75
Study 20493642 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy to 70 Gy
Number of subjects: 301
Study 20493642 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to 78 Gy
Number of subjects: 301
Study 20493642 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy to 70 Gy for patients <70 years old
Number of subjects: 301
Study 20493642 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to 78 Gy for patients <70 years old
Number of subjects: 301
Study 20493642 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy to 70 Gy for patients age 70 or older
Number of subjects: 301
Study 19894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatretenone 45 mg three times a day
Number of subjects: 0
Study 19894328 — intervention group
Group type: COMPARATOR
Intervention: Menatretenone 45 mg twice a day
Number of subjects: 0
Study 16735933 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of hormone therapy (group 1)
Number of subjects: 91
Study 16735933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual discontinuation of hormone therapy (group 2)
Number of subjects: 91
Study 16735933 — intervention group
Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 91
Study 15367481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing portrait only
Number of subjects: 200
Study 15367481 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational module only
Number of subjects: 200
Study 15367481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both portrait and module
Number of subjects: 200
Study 15367481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 11343044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF), EleCare, followed for a median of 21 months (range 7 to 40 months)
Number of subjects: 31
Study 11343044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF), EleCare
Number of subjects: 31